ClinicalTrials.gg
CompletedNCT02097719Updated Jan 14, 2016Results posted

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

A Phase 4 interventional study of bimatoprost 0.01% and travoprost 0.004% in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing bimatoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Bimatoprost · Glaucoma.

Enrollment
16th of 23
100 · median 144
Started
2014
the only one that year
Phase 4
17 of 27
none open now
Registered
22nd of 27
by date
Lead sponsor
12 of 27
Allergan

Among the 27 studies testing bimatoprost in Glaucoma, this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2014, is one of 17 in phase 4, and was the 22nd registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 27 studies testing bimatoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About bimatoprost

Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing bimatoprost in Glaucoma as a file.
02

Study summary

This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ocular hypertension or glaucoma that requires treatment with medication
  • Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
  • History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
  • Use of topical, periorbital, intravitreal or systemic within 3 months or expected use during the course of study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    bimatoprost 0.01% and hypromellose 0.3%

    Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.

    Drug: bimatoprost 0.01% · Drug: hypromellose 0.3%

  • Active comparator
    travoprost 0.004% and timolol 0.5%

    Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.

    Drug: travoprost 0.004% · Drug: timolol 0.5%

Interventions

  • Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.

    Also known as: Lumigan® RC, Lumigan®

  • Travoprost 0.004% administered to both eyes once daily for 12 weeks.

    Also known as: Travatan Z®

  • Timolol 0.5% administered to both eyes once daily for 12 weeks.

    Also known as: Timolol Maleate-EX, Timolol GFS

  • Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.

    Also known as: GenTeal®

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM

    IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.

    Time frame: Week 12 at 8 AM, 12 PM, and 4 PM

07

Results

Posted Jan 14, 2016

Participant flow

Participant flow — Overall Study
MilestoneBimatoprost 0.01% and Hypromellose 0.3%Travoprost 0.004% and Timolol 0.5%
Started4951
Completed4650
Not completed31
Withdrew: Subject withdrew consent10
Withdrew: Lost to follow-up01
Withdrew: Adverse event20

Outcome measures

PrimaryIntraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM

IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.

Time frame:
Week 12 at 8 AM, 12 PM, and 4 PM
Reported as:
Mean · Millimeters of Mercury (mmHg)
Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
Millimeters of Mercury (mmHg)Bimatoprost 0.01% and Hypromellose 0.3%Travoprost 0.004% and Timolol 0.5%
Week 12 at 8 AM (N=46, 50)16.7 ± 0.5015.4 ± 0.48
Week 12 at 12 PM (N=46, 50)16.2 ± 0.4315.6 ± 0.54
Week 12 at 4 PM (N=47, 50)16.0 ± 0.4615.4 ± 0.60

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimatoprost 0.01% and Hypromellose 0.3%—0/49 (0%)0/49 (0%)
Travoprost 0.004% and Timolol 0.5%—0/51 (0%)0/51 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bimatoprost 0.01% and Hypromellose 0.3%Travoprost 0.004% and Timolol 0.5%Total
Mean63.5 ± 11.7365.5 ± 9.9864.5 ± 10.86
Sex: Female, Male
Sex: Female, Male(Participants)Bimatoprost 0.01% and Hypromellose 0.3%Travoprost 0.004% and Timolol 0.5%Total
Female262046
Male233154
08

Study locations

1 site
  • Racine, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2014
First posted
Mar 27, 2014
Start
May 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Jan 14, 2016
Last update
Jan 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02097719
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Mar 27, 2014
Start date
May 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jan 14, 2016
Last update
Jan 14, 2016

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimatoprost · Travoprost · Timolol · Hypromellose Derivatives

Start the discussion